Innate Pharma will focus R&D on monoclonal antibodies

03/6/2010 | Reuters

Innate Pharma said it will concentrate on the development of monoclonal antibodies while halting the development of some experimental drugs, including IPH 1101 for the indication of chronic blood cancer and two RNA-based drug candidates. "The [RNA candidate] projects will not be binned, but we will try to find buyers to continue them," said Laure-Helene Mercier, head of the firm's investor relations.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX